JOSEPH OHAYON – CHIEF FINANCIAL OFFICER, COMPANY SECRETARY & EXECUTIVE DIRECTOR
Joseph Ohayon joined the company in July 2010 as the Chief Financial Officer and in March 2011 he took over the role of Company Secretary and then became an Executive Director and member of the Board in December 2012. He has over 20 years experience in financial roles including 12 years within health-related industries. Joseph qualified as a Chartered Accountant in the UK and graduated with a Masters of Business Administration in International Business from Murdoch University in 2007.
CAROL WORTH – CHIEF TECHNICAL MANAGER
Dr. Worth has been working in the area of drug delivery systems for over 25 years at various international companies. As a development chemist, she liaised between companies in USA, UK and Asia to develop oral formulations of injectable peptide hormones. She has since been involved in the development of novel anticancer drugs and, most recently, topical pain relief formulations. She has extensive experience in the setting up and running of GMP accredited laboratories and development of robust products suitable for GMP manufacturing. Dr. Worth has a PhD in Natural Product Chemistry from the University of Western Australia.
DAVID PHILLIPS – NON-EXECUTIVE DIRECTOR
David Phillips joined the Board as a Non-Executive Director in April 2018. He has 30 years of experience in the global healthcare industry, including Glaxo Wellcome, Cephalon Inc, Oxford Molecular Group Plc and SR One (GlaxoSmithKline’s corporate venture fund). David spent 12 years at Board level as Chief Business Officer of Argenta Discovery, The Automation Partnership and BioFocus PLC. David re-joined GlaxoSmithKline’s (GSK) SR One corporate venture arm in 2008 to pioneer a new function to incubate and spin-out technologies from GSK and in parallel investing in early-stage life science companies.
ANDREW CURTIS – VICE PRESIDENT, BUSINESS DEVELOPMENT & ALLIANCE MANAGEMENT (BASED IN THE USA)
Andrew Curtis – Vice President, Business Development and Licensing (US based)
Andrew leads the Company’s US and European business development efforts, including the out-licensing of SUDA’s portfolio of programs, the development of industry partnerships, and leading the presence SUDA’s US-based commercial efforts.
Andrew has held senior management roles at Genzyme-Sanofi, Merck, J&J, and Pfizer, in a range of commercial functions, including Corporate Strategy, Business Development, Commercial Development, and Sales and Marketing. He has also worked in the biotech sector for two German companies, Jerini and Affimed. Additionally, Andrew founded Rising Tide Therapeutics, a novel biotech entity focused on finding a cure for alpha antitrypsin deficiency, a rare genetic pulmonary disease.
Andrew has broad therapeutic experience in Rare Diseases, Oncology, CNS, Pain, Wound Healing, Biosimilars, and Metabolic Bone Disease. He will be based in the US.
Dr Deborah Cooper is a Biotech professional with 25 years (12 at the executive level and 5 as a consultant). Background in Cell Biology/Immunology, Clinical Manufacturing and product development as well as Project Management.